Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Diluent

ApprovedBiologic

Diluent is one of 175 biologic programs targeting Insulin resistance. It is currently in Approved.

6

Indications

7

Total Trials

1

Active Trials

174

Competitors

Pipeline

Status by Indication[3][1]

Indication

Insulin ResistanceActive, not recruiting

RhinitisActive, not recruiting

Pulmonary HypertensionActive, not recruiting

Bipolar DisorderActive, not recruiting

Neovascular Age-Related Macular DegenerationRecruiting

Age-Related Macular DegenerationActive, not recruiting

Insulin ResistancePhase 1/Phase 2

Active, not recruiting

RhinitisApproved

Active, not recruiting

Pulmonary HypertensionPhase 3

Active, not recruiting

Bipolar DisorderPhase 3

Active, not recruiting

Neovascular Age-Related Macular DegenerationPreclinical

Recruiting

Age-Related Macular DegenerationPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

237 competitors in Age-Related Macular Degeneration

#DrugCompanyPhaseTrials

Lucentis

Eylea

Vabysmo

Beovu

Macugen

Avastin

BBio-Thera Solutions

Diluent

Retaane

AAlcon Research

Kenalog

BBausch Health Americas, Inc.

Forzinity

SStealth BioTherapeutics Inc.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2031

PreclinicalRecruiting

Neovascular Age-Related Macular Degeneration

NCT06660667

Clinical

Trials by Indication[1]

Gene Expression1 trial

Differential Gene Expression in Lung and Peripheral Blood After Inhaled Allergen Challenge

Terminated·JJohn Sundy·Phase 1·NCT00671593·40 enrolled

Hypersensitivity1 trial

Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens

Terminated·TTonix Pharmaceuticals, Inc.·Phase 1·NCT05216510·9 enrolled

Rhinitis1 trial

Mechanisms of Capsaicin Treatment in Idiopathic Rhinitis Patients and Controls

Completed·UUniversitaire Ziekenhuizen KU Leuven·Phase 4·NCT01862523·39 enrolled

Pulmonary Hypertension1 trial

Sildenofil in Persistent Pulmonary Hypertension in Newborns

Unknown status·HHamad Medical Corporation·Phase 3·NCT01558466·100 enrolled

Bipolar Disorder1 trial

The Effect of Intranasal Insulin on Neurocognitive Function in Euthymic Patients With Bipolar Disorder

Completed·UUniversity Health Network, Toronto·Phase 3·NCT00314314·60 enrolled

2 more indications

Insulin resistance1 trial

Brain Insulin Resistance in Mood Disorders

Unknown status·UUniversity Health Network, Toronto·Phase 1/2·NCT03915613·150 enrolled

Neovascular Age-related Macular Degeneration1 trial

A Phase 1/2 Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, and Efficacy of One-time Intravitreal Dose of SAR402663 in Participants With Neovascular Age-related Macular Degeneration

Recruiting· Sanofi logo

Sanofi·Preclinical·NCT06660667·66 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Diluent. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Diluent compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Diluent. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Approved[1]
Company: Sanofi

Related News